This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
Dolutegravir plus lamivudine shows comparable efficacy and safety with standard-of-care three-drug regimen in patients with HIV without preliminary drug resistance testing in a phase 4 trial.
Medscape Medical News